Hepatitis C Infection: A Systematic Disease

Clinics in Liver Disease

Volumn 21, Issue 3, 2017, Pages 449-453

  Younossi, Zobair M ^a,b  

^a BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^b INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Extrahepatic complications; Hepatic complications; Hepatitis C virus

Indexed keywords

HEPATITIS ANTIBODY;

CHRONICITY; CLINICAL OUTCOME; COMORBIDITY; DECOMPENSATED LIVER CIRRHOSIS; GEOGRAPHICAL VARIATION (SPECIES); GEOGRAPHY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MORTALITY RISK; NONHUMAN; QUALITY OF LIFE; REVIEW; SPECIES DISTRIBUTION; SURVIVAL RATE; VIRUS CARRIER; CHRONIC HEPATITIS C; COMPLICATION; COST OF ILLNESS; ECONOMICS;

COST OF ILLNESS; HEPATITIS C, CHRONIC; HUMANS;

EID: 85018640297     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2017.03.001     Document Type: Review

References (56)

1. Williams, I.T., Bell, B.P., Kuhnert, W., et al. Incidence and transmission patterns of acute hepatitis C in the United States, 1982-2006. Arch Intern Med 171:3 (2011), 242–248.
2. Alter, M.J., Margolis, H.S., Krawczynski, K., et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N Engl J Med 327:27 (1992), 1899–1905.
3. Purcell, R.H., Walsh, J.H., Holland, P.V., et al. Seroepidemiological studies of transfusion-associated hepatitis. J Infect Dis 123 (1971), 406–413.
4. Gower, E., Estes, C., Blach, S., et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:1 Suppl (2014), S45–S57.
5. Hajarizadeh, B., Grebely, J., Dore, G.J., Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:9 (2013), 553–562.
6. Leone, N., Rizzetto, M., Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma. Minerva Gastroenterol Dietol 51:1 (2005), 31–46.
7. Westbrook, R.H., Dusheiko, G., Natural history of hepatitis C. J Hepatol 61:1 Suppl (2014), S58–S68.
8. Messina, J.P., Humphreys, I., Flaxman, A., et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 61:1 (2015), 77–87.
9. Liakina, V., Hamid, S., Tanaka, J., et al. Historical epidemiology of hepatitis C virus (HCV) in select countries. J Viral Hepat 22:Suppl 4 (2015), 4–20.
10. Zalesak, M., Francis, K., Gedeon, A., et al. Current and future disease progression of the chronic HCV population in the United States. PLoS One, 8(5), 2013, e63959.
11. Castells, L., Vargas, V., Gonzalez, A., et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 15:3 (1995), 159–163.
12. Donato, F., Boffetta, P., Puoti, M., A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75:3 (1998), 347–354.
13. Gordon, S.C., Bayati, N., Silverman, A.L., Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 28:2 (1998), 562–567.
14. Younossi, Z., Park, H., Henry, L., et al. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150:7 (2016), 1599–1608.
15. Younossi, Z.M., Tanaka, A., Eguchi, Y., et al. The impact of hepatitis C virus outside the liver: evidence from Asia. Liver Int 37:2 (2017), 159–172.
16. Younossi, Z.M., Birerdinc, A., Henry, L., Hepatitis C infection: a multi-faceted systemic disease with clinical, patient reported and economic consequences. J Hepatol 65:1 Suppl (2016), S109–S119.
17. Fattovich, G., Stroffolini, T., Zagni, I., et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127 (2004), S35–S50.
18. Lee, M.H., Yang, H.I., Lu, S.N., et al., R.E.V.E.A.L.-HCV Study Group. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 206:4 (2012), 469–477.
19. Cammà, C., Bruno, S., Di Marco, V., et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 43:1 (2006), 64–71.
20. Ortiz, V., Berenguer, M., Rayon, J.M., et al. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroentrol 97:9 (2002), 2408–2414.
21. D'Souza, R., Sabin, C.A., Foster, G.R., Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroentrol 100:7 (2005), 1509–1515.
22. Calvaruso, V., Craxì, A., Immunological alterations in hepatitis C virus infection. World J Gastroenterol 19:47 (2013), 8916–8923.
23. Hung, C.H., Lee, C.M., Lu, S.N., Hepatitis C virus-associated insulin resistance: pathogenic mechanisms and clinical implications. Expert Rev Anti Infect Ther 9:5 (2011), 525–533.
24. Davis, G.L., Alter, M.J., El-Serag, H., et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 138:2 (2010), 513–521 521.e1-6.
25. Taylor, A.L., Denniston, M.M., Klevens, R.M., et al. Association of hepatitis C virus with alcohol use among U.S. adults: NHANES 2003-2010. Am J Prev Med 51:2 (2016), 206–215.
26. Ly, K.N., Hughes, E.M., Jiles, R.B., et al. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis 62:10 (2016), 1287–1288.
27. D'Amico, G., Pasta, L., Morabito, A., et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther 39:10 (2014), 1180–1193.
28. Fattovich, G., Giustina, G., Degos, F., et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 112:2 (1997), 463–472.
29. Serfaty, L., Aumaître, H., Chazouillères, O., et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 27:5 (1998), 1435–1440.
30. Hu, K.Q., Tong, M.J., The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 29:4 (1999), 1311–1316.
31. Younossi, Z.M., Singer, M.E., Mir, H.M., et al. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 60:3 (2014), 530–537.
32. Cacoub, P., Comarmond, C., Domont, F., et al. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis 3:1 (2016), 3–14.
33. Petta, S., Maida, M., Macaluso, F.S., et al. Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies. Gastroenterology 150 (2016), 145–155.e4.
34. Domont, F., Cacoub, P., Chronic hepatitis C virus infection, a new cardiovascular risk factor?. Liver Int 36 (2016), 621–627.
35. Younossi, Z., Kallman, J., Kincaid, J., The effects of HCV infection and management on health-related quality of life. Hepatology 45:3 (2007), 806–816.
36. Younossi, Z.M., Chronic liver disease and health-related quality of life. Gastroenterology 120:1 (2001), 305–307.
37. Afendy, A., Kallman, J.B., Stepanova, M., et al. Predictors of health-related quality of life in patients with chronic liver disease. Aliment Pharmacol Ther 30:5 (2009), 469–476.
38. Dan, A.A., Crone, C., Wise, T.N., et al. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life. Psychosomatics 48:3 (2007), 223–229.
39. Kallman, J., O'Neil, M.M., Larive, B., et al. Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection. Dig Dis Sci 52:10 (2007), 2531–2539.
40. Bonkovsky, H.L., Snow, K.K., Malet, P.F., et al., HALT-C Trial Group. Health-related quality of life in patients with chronic hepatitis C and advanced fibrosis. J Hepatol 46:3 (2007), 420–431.
41. Younossi, Z.M., Boparai, N., Price, L.L., et al. Health-related quality of life in chronic liver disease: the impact of type and severity of disease. Am J Gastroenterol 96 (2001), 2199–2205.
42. Spiegel, B.M., Younossi, Z.M., Hays, R.D., et al. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 41 (2005), 790–800.
43. Loria, A., Doyle, K., Weinstein, A.A., et al. Multiple factors predict physical performance in people with chronic liver disease. Am J Phys Med Rehabil 93:6 (2014), 470–476.
44. Younossi, Z.M., Jiang, Y., Smith, N.J., et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: insights from a work productivity economic model from the United States. Hepatology 61:5 (2015), 1471–1478.
45. Younossi, Z., Brown, A., Buti, M., et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. J Viral Hepat 23:3 (2016), 217–226.
46. DiBonaventura, M.D., Wagner, J.S., Yuan, Y., et al. The impact of hepatitis C on labor force participation, absenteeism, presenteeism and non-work activities. J Med Econ 14:2 (2011), 253–261.
47. Su, J., Brook, R.A., Kleinman, N.L., et al. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 52:2 (2010), 436–442.
48. Younossi, Z.M., Stepanova, M., Feld, J., et al. Sofosbuvir and velpatasvir combination improves outcomes reported by patients with HCV infection, without or with compensated or decompensated cirrhosis. Clin Gastroenterol Hepatol, 2016, 10.1016/j.cgh.2016.10.037.
49. Younossi, Z.M., Stepanova, M., Sulkowski, M., et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat 23:11 (2016), 857–865.
50. Younossi, Z.M., Stepanova, M., Sulkowski, M., et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and -3 clinical trials. Clin Infect Dis 63:8 (2016), 1042–1048.
51. Younossi, Z.M., Stepanova, M., Henry, L., et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. Am J Gastroenterol 111:6 (2016), 808–816.
52. Younossi, Z.M., Stepanova, M., Henry, L., et al. Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus. J Viral Hepat 23:8 (2016), 623–630.
53. Younossi, Z.M., Stepanova, M., Feld, J., et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial. J Hepatol 65:1 (2016), 33–39.
54. Younossi, Z.M., Stepanova, M., Chan, H.L., et al. Patient-reported outcomes in Asian patients with chronic hepatitis C treated with ledipasvir and sofosbuvir. Medicine (Baltimore), 95(9), 2016, e2702.
55. Younossi, Z.M., Stepanova, M., Nader, F., et al. Patient-reported outcomes of elderly adults with chronic hepatitis C treated with interferon- and ribavirin-free regimens. J Am Geriatr Soc 64:2 (2016), 386–393.
56. Younossi, Z.M., Stepanova, M., Pol, S., et al. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int 36:1 (2016), 42–48.